首页> 外文期刊>Diabetes >The relationship between plasma osteoprotegerin and endothelium-dependent arterial dilation in type 2 diabetes.
【24h】

The relationship between plasma osteoprotegerin and endothelium-dependent arterial dilation in type 2 diabetes.

机译:2型糖尿病患者血浆骨保护素与内皮依赖性动脉扩张之间的关系。

获取原文
获取原文并翻译 | 示例
       

摘要

Osteoprotegerin is a recently identified inhibitor of bone resorption. Recent studies indicate that osteoprotegerin also acts as an important regulatory molecule in the vasculature. The purpose of this study was to investigate the relationship between plasma osteoprotegerin levels and endothelium-dependent arterial dilation in type 2 diabetic patients. The study subjects included 40 newly diagnosed type 2 diabetic patients and 46 healthy subjects. All patients were given insulin therapy for 6 months. Plasma osteoprotegerin concentration was measured in duplicate by a sandwich enzyme-linked immunosorbent assay method, and high-resolution ultrasound was used to measure brachial artery diameter at rest, after reactive hyperemia, and after sublingual glyceryltrinitrate. The plasma osteoprotegerin level in patients before treatment was 3.36 +/- 0.32 ng/l, which was significantly higher than that in control subjects (2.38 +/- 0.25 ng/l, P < 0.001). After 6 months of treatment, osteoprotegerin levels decreased markedly (2.83 +/- 0.34 ng/l, P < 0.001). Flow-mediated endothelium-dependent arterial dilation in patients before treatment was 3.21 +/- 0.52%, which was significantly lower than that in control subjects (4.46 +/- 0.56%, P < 0.01), and it improved markedly after 6 months of treatment (4.03 +/- 0.49%, P < 0.01). In multivariate analysis, osteoprotegerin was significantly associated with endothelium-dependent arterial dilation, fasting blood glucose (FBG), HbA(1c) (A1C), and ultrasensitive C-reactive protein (CRP) at baseline (P < 0.01). The absolute changes in osteoprotegerin showed significant correlation with changes in endothelium-dependent arterial dilation, FBG, A1C, and CRP in diabetic patients during the course of treatment (P < 0.01). This study shows that plasma osteoprotegerin levels are elevated in newly diagnosed diabetic patients and are significantly associated with endothelial function.
机译:骨保护素是最近发现的骨吸收抑制剂。最近的研究表明,骨保护素在血管系统中也起着重要的调节分子的作用。这项研究的目的是调查2型糖尿病患者血浆骨保护素水平与内皮依赖性动脉扩张之间的关系。研究对象包括40名新诊断的2型糖尿病患者和46名健康受试者。所有患者均接受了6个月的胰岛素治疗。通过三明治酶联免疫吸附测定法一式两份测量血浆骨保护素浓度,并使用高分辨率超声测量静息时,反应性充血后和舌下三硝酸甘油酯后的肱动脉直径。治疗前患者血浆骨保护素水平为3.36 +/- 0.32 ng / l,明显高于对照组(2.38 +/- 0.25 ng / l,P <0.001)。治疗6个月后,骨保护素水平显着下降(2.83 +/- 0.34 ng / l,P <0.001)。治疗前患者的血流介导的内皮依赖性动脉扩张为3.21 +/- 0.52%,显着低于对照组(4.46 +/- 0.56%,P <0.01),并且在6个月的治疗后明显改善治疗(4.03 +/- 0.49%,P <0.01)。在多变量分析中,骨保护素与基线时的内皮依赖性动脉扩张,空腹血糖(FBG),HbA(1c)(A1C)和超敏C反应蛋白(CRP)显着相关(P <0.01)。在治疗过程中,糖尿病患者中骨保护素的绝对变化与内皮依赖性动脉扩张,FBG,A1C和CRP的变化呈显着相关性(P <0.01)。这项研究表明,新诊断的糖尿病患者血浆骨保护素水平升高,并且与内皮功能显着相关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号